Displaying 2521 - 2540 of 4804
Pfizer Inc./Hospira, Inc., In the Matter of
Pfizer Inc. agreed to sell the rights and assets related to four pharmaceutical products in order to settle FTC charges that its proposed $16 billion acquisition of Hospira, Inc. would likely be anticompetitive. Pfizer is one of the world’s largest drug companies and principally competes with Hospira in markets for certain sterile injectable pharmaceutical products. The order requires Pfizer to supply Alvogen with the clindamycin phosphate injection product for three years while Pfizer transfers the manufacturing technology to Alvogen or its designee. Pfizer also is required to provide transitional services to Alvogen to assist with establishing manufacturing capabilities and securing FDA approvals to market all of the divested products.
15100001 Informal Interpretation
Two Pennsylvania Orthopedic Practices Settle FTC Charges That Merger Harmed Competition and Inflated Prices
In Comments Submitted to Virginia and Tennessee Health Departments FTC Staff Offers Assistance in Evaluating Proposed Hospital Cooperation Agreements
FTC Chairwoman Ramirez Testifies Before Congress on Legislation That Would Alter the Agency’s Role in Adjudicating Merger Cases
Investor Len Blavatnik to Pay $656,000 to Settle FTC Charges That He Violated U.S. Premerger Notification Requirements
1509006 Informal Interpretation
FTC Files Amicus Brief Explaining that Pharmaceutical “Product Hopping” Can Violate the Antitrust Laws
1509005 Informal Interpretation
Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.
FTC Requires Divestitures Prior to Merger of Orthopedic Device Companies
1509004 Informal Interpretation
1509003 Informal Interpretation
1509002 Informal Interpretation
Displaying 2521 - 2540 of 4804